Tag
This review synthesizes recent evidence on machine learning models integrating multimodal data for relapse prediction in MDD, highlighting moderate accuracy driven mainly by clinical risk factors and advocating for dynamic approaches to bet
This article critically examines the FDA’s approval of gepirone ER for major depressive disorder despite multiple negative trials, highlighting regulatory flexibility, statistical and clinical considerations, and implications for tran
In a 16-week randomized trial, adjunctive oral semaglutide improved effort-based decision-making in adults with major depressive disorder and overweight or obesity, suggesting a potential role for GLP-1 receptor agonism in reward-related dy
A double-blind RCT involving 240 patients reveals that combining rTMS and tDCS significantly improves remission rates and symptom reduction in Major Depressive Disorder with comorbid anxiety compared to single-modality or sham treatments, p
A landmark one-year actigraphy study reveals that sleep phase variability and daily activity amplitude are significant objective markers for predicting MDD relapse, offering a scalable path toward personalized, preventive psychiatric care.
A large-scale retrospective cohort study identifies specific phenotypic traits and genetic markers, including the SLAMF3/LY9 locus, that predict antidepressant treatment complexity and sustained use, offering a roadmap for precision psychia
A multi-center randomized clinical trial involving 257 youths found that adjunctive omega-3 fatty acids (1.5 g/d) did not outperform placebo in treating moderate-to-severe pediatric major depressive disorder, despite high adherence and conc
This RCT reveals that adults with major depressive disorder and elevated systemic inflammation exhibit heightened anhedonic responses to an inflammatory challenge, highlighting inflammation’s role in depression symptomatology.
A multi-site fMRI study demonstrates that effective connectivity patterns between the cerebellum and fronto-temporal areas accurately classify major depressive disorder with over 94% accuracy, offering a promising neuroimaging biomarker to
Azetukalner, a KV7 potassium channel opener, demonstrated clinically meaningful antidepressant effects and significant improvement in anhedonia in adults with major depressive disorder in a 6-week randomized trial, supporting further develo
This analysis explores how soft drink consumption correlates with major depressive disorder (MDD), revealing gut microbiome alterations—particularly in Eggerthella abundance—that may mediate this association, highlighting potential interven
A phase 2 trial in adults with major depressive disorder demonstrated that ammoxetine at 40 mg/d and 60 mg/d significantly improved depressive symptoms compared to placebo and was generally well tolerated, offering a novel treatment option
The AID-ME trial demonstrates that an AI-powered clinical decision support system significantly improves remission rates and accelerates symptom improvement in moderate to severe major depressive disorder.
A randomized clinical trial in Pakistan demonstrates that measurement-based care accelerates antidepressant treatment response and remission in major depressive disorder compared to standard care, underscoring its potential in low-resource
This analysis reveals that varenicline is the most effective and safe pharmacotherapy for smoking cessation in individuals with current or past major depressive disorder, outperforming bupropion and nicotine patches with no increased neurop
A scoping review of 209 trials reveals a concentrated evidence base for omega-3s, St John’s Wort, saffron, probiotics, and vitamin D in treating adult depression, highlights promising but under-researched herbal and supplement candidates, a
